drugset / Trial / NCT06857955
A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients
RandomizedParallel-groupTriple-blindOther
Summary
The purpose of this study is to evaluate the efficacy, safety and tolerability of QCZ484 or placebo, given subcutaneously, every 6 months, at different dose levels in patients with mild to moderate hypertension
Timeline
- Start
- 2025-03-26
- Primary completion
- 2027-01-29
- Completion
- 2028-04-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | QCZ484 | Unknown | — | Subcutaneous |